Recent patents for pharmaceutical compounds comprising and treatments using histone deacetylase and DNA methyltransferase inhibitors.
Patent number | Description | Assignee | Inventor | Date |
---|---|---|---|---|
US 10,576,066 | A method for modulating programmed death receptor ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also, a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a HDAC inhibitor and a composition comprising a therapeutically effective amount of a PDL1 inhibitor, a programmed death 1 receptor inhibitor, or a combination thereof. | H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL, USA) | Villagra AV, Sotomayor EM | 3/3/2020 |
US 10,544,156 | A compound or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNA methyltransferase inhibitor, in particular in the treatment of cancer. | Pierre Fabre Medicament (Boulogne-Billancourt, France), Centre National de la Recherche Scientifique (Paris) | Halby L, Menon Y, Kaloun EB, Long C, Arimondo PB | 1/28/2020 |
US 10,537,535 | Compounds that act as HDAC inhibitors and can affect expression of genes in vivo and in vitro. Such inhibitors can be used as therapeutics for numerous disease conditions, such as a variety of cancers, neural degenerative diseases, neurological diseases, senescence and infectious diseases. | The Regents of the University of California (Oakland, CA, USA) | Ray A, Yamanaka S | 1/21/2020 |
US 10,538,498 | Novel compounds having HDAC6 inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. | Chong Kun Dang Pharmaceutical (Seoul) | Lee J, Han Y, Kim Y, Choi D, Min J, Bae M, Yang H, Kim D | 1/21/2020 |
US 10,532,053 | A 4-arylamino quinazoline hydroxamic acid compound having a HDAC inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a HDAC inhibitor medicine. | Guangdong Zhongsheng Pharmaceutical (Guangdong, China) | Chen L, Long C, Chen X, Liu Z, Ye H, Xie C | 1/14/2020 |
US 10,533,003 | Polyheteroaryl HDAC inhibitors. | Karus Therapeutics (Oxfordshire, UK) | Shuttleworth SJ, Cecil AR, MacCormick S, Nodes WJ, Tomassi CD, Silva FA | 1/14/2020 |
US 10,519,149 | Compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, that are useful in the treatment of conditions associated with inhibition of histone deacetylase (e.g., HDAC2). | Rodin Therapeutics (Boston) | Fuller NO, Lowe JA III | 12/31/2019 |
US 10,508,122 | Novel hydroxamic acids that are specific HDAC inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, that are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation. | The Regents of the University of Colorado (Denver) | Liu X, Zhang G, Chan DC-F, Piscopio AD | 12/17/2019 |
Rights and permissions
About this article
Cite this article
Epigenetic drugs. Nat Biotechnol 38, 558 (2020). https://doi.org/10.1038/s41587-020-0523-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0523-2